Taro Pharmaceutical Industries Ltd. (TARO)

Last Closing Price: 30.77 (2023-02-01)

Company Description

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $561.35M
Net Income (Most Recent Fiscal Year) $58.27M
PE Ratio (Current Year Earnings Estimate) 42.74
PE Ratio (Trailing 12 Months) 25.22
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 2.03
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.68
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 7.59
Pre-Tax Margin (Trailing 12 Months) 13.29%
Net Margin (Trailing 12 Months) 8.06%
Return on Equity (Trailing 12 Months) 2.69%
Return on Assets (Trailing 12 Months) 2.15%
Current Ratio (Most Recent Fiscal Quarter) 3.62
Quick Ratio (Most Recent Fiscal Quarter) 3.04
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) 1.39
Book Value per Share (Most Recent Fiscal Quarter) $45.54
Earnings per Share (Most Recent Fiscal Quarter) $0.19
Earnings per Share (Most Recent Fiscal Year) $3.36
Diluted Earnings per Share (Trailing 12 Months) $1.22
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Common Shares Outstanding 37.58M
Free Float 32.40M
Market Capitalization $1.16B
Average Volume (Last 20 Days) 9187.20
Beta (Past 60 Months) 0.66
Percentage Held By Insiders (Latest Annual Proxy Report) 13.80%
Percentage Held By Institutions (Latest 13F Reports) 11.45%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%